Clinical trials: Anthrax Infection
Healthy
Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change
Anthrax Clinical Trial Objectives: To assess whether: Anthrax vaccine (AVA or BioThrax, BioPort Corp. Lansing MI) administered by the intramuscular (IM) route elicits antibody responses that are not inferior (i.e.…
- Trial name
- AVRP (NCT00119067)
- Testing
- Anthrax Vaccine Adsorbed, Saline injection
- Where
- 5 sites in United States
- Volunteers
- 1,564 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Bacillus Anthracis (Anthrax)
Monoclonal Antibody for Treatment of Inhalation Anthrax
The purpose of this study is to evaluate the safety and pharmacokinetics (how long a drug stays in the bloodstream and how high the levels of the drug are at different times) of ETI-204 following intravenous (IV-into a vein)…
- Trial name
- NCT00138411
- Testing
- Ciprofloxacin 500 mg, ETI-204 (Anthim)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dental Plaque
Comparative Clinical Assessment of Charcoal and Conventional Toothbrushes
Oral hygiene practices are fundamental to maintaining oral health, preventing dental plaque accumulation, halitosis, stains, gingival and periodontal diseases, and improving overall quality of life.
- Trial name
- NCT07563413
- Testing
- charcoal toothbrush
- Where
- Egypt
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Cairo University
Inhalational Anthrax
Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers
To evaluate the safety, tolerability, pharmacokinetics and immunogenicity of repeat administration (two doses) of intravenous (IV) ETI-204.
- Trial name
- NCT01932242
- Testing
- ETI-204
- Where
- 2 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Elusys Therapeutics
Therapeutic Treatment of Inhalation Anthrax
An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection
This is an open-label study to evaluate the immunogenicity and safety of raxibacumab in healthy adult male and female subjects. Subjects who have received raxibacumab >= 4 months ago will be enrolled and dosed as follows: A…
- Trial name
- NCT02016963
- Testing
- Raxibacumab
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Human Genome Sciences Inc.
Healthy
Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects
Rivaroxaban is a direct oral anticoagulant that target specifically activated factor X. Bleeding events related to rivaroxaban are the consequence of physiopathologic, pharmacokinetic issues or poisoning.
- Trial name
- RICHAR (NCT02657512)
- Testing
- rivaroxaban, rivaroxaban and activated charcoal
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Anthrax
Ph1 Study of Valortim and Doxycycline in Humans
The purpose of this study is to evaluate the safety and tolerability of short-term dosing of IV doxycycline when administered concomitantly with IV Valortim in normal healthy human subjects.
- Trial name
- NCT00964834
- Testing
- Doxycycline and Valortim
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- PharmAthene, Inc.
Anthrax
Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.
The goal of this observational study is to evaluate the safety and clinical benefit of two doses of CYFENDUS vaccine when used with the concurrent recommended antibacterial regimen for post-exposure prophylaxis to prevent…
- Trial name
- NCT07268612
- Testing
- CYFENDUS
- Volunteers
- 250 people
- Sponsor
- Emergent BioSolutions
Bacillus Anthracis (Anthrax)
UMD rPA Regimen Trial in Adults
Objectives are: To confirm the safety and tolerability of 2-dose regimens of 100 g rPA vaccines (3 products) administered by the intramuscular (IM) route to healthy adults.To describe the immunologic responses to 2-dose regimens…
- Trial name
- NCT00133484
- Testing
- Anthrax vaccine absorbed made from Bacillus anthracis (AVA), Recombinant protein antigen (rPA) made from Bacillus anthrax, Recombinant protein antigen (rPA) made from Escherichia coli
- Where
- 2 sites in United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Anthrax
A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109
The purpose of this study is to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Administered in Multi Intramuscular Doses to Healthy Subjects.
- Trial name
- GC1109 (NCT01624532)
- Where
- South Korea
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Air or Gas Embolism, Carbon Monoxide Poisoning
Hyperbaric Oxygen Therapy Registry
The purpose of the Hyperbaric Oxygen Therapy Registry (HBOTR) is to provide real world patient outcome and side effect information from electronic health records submitted to a specialty specific hyperbaric registry as part of…
- Conditions
- Air or Gas Embolism, Carbon Monoxide Poisoning, Clostridial Myositis and Myonecrosis (Gas Gangrene), Crush Injury, Compartment Syndrome & Other Acute Traumatic Ischemias
- Trial name
- HBOTR (NCT02483650)
- Volunteers
- 5,000 people
- Sponsor
- U.S. Wound Registry
Healthy Volunteers
NasoShield in Healthy Adults to Study Safety and Immunogenicity
The purpose of this study is to evaluate the safety for up to two doses of NasoShield, to determine if antibodies that protect against anthrax are formed after treatment with NasoShield, and to determine whether the formation of…
- Trial name
- NCT04415749
- Testing
- NasoShield
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Healthy Adult Volunteers
A Pilot Feasibility Study of Activated Charcoal in Healthy Volunteers
This is a pilot study designed to test feasibility, tolerability, and safety of medical grade oral Activated Charcoal (AC) in 12 healthy volunteers. To determine the two most palatable and tolerable AC combinations.
- Trial name
- NCT04204772
- Testing
- Activated charcoal and Tap Water, Activated Charcoal and Apple Juice
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Smoking ( Cigarette)
Cigarette Filter Study
The overall purpose of this study is to determine the effects of using charcoal-filtered cigarettes on product perceptions, smoking behaviors, and biomarkers of exposure to tobacco-related toxicants.
- Trial name
- NCT07348679
- Testing
- Charcoal filtered cigarettes with marketing, Charcoal filtered cigarette without marketing, Non-charcoal filtered cigarettes
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- Rutgers, The State University of New Jersey
Healthy Participants
A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants
The purpose of this study is to evaluate the effects of co-administration of activated charcoal with sorbitol on the single-dose drug levels of mavacamten in healthy participants.
- Trial name
- NCT05320094
- Testing
- Mavacamten, Activated Charcoal with Sorbitol
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Severe Poisoning With Cardiotropic or Psychotropic Drug, Admission to Intensive Care
Combined Gastrointestinal Decontamination in Acute Severe Poisoning
Gastrointestinal absorption of high dose medication (toxicant) ingested under solid form for suicidal purposes, is prolonged in patients who need intensive care admission and mechanical ventilation.
- Trial name
- DIMREATOX (NCT07201311)
- Testing
- Combination of activated charcoal with polyethylene glycol for digestive decontamination, Standard Treatment (Guideline-Based)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ischemic Stroke, Malignant Edema
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
This is a randomized, multi-center, prospective, double blind study. The primary objective is to assess the efficacy and safety of glyburide (RP-1127) compared to placebo in participants with a severe anterior circulation…
- Trial name
- GAMES-RP (NCT01794182)
- Testing
- Glyburide for Injection
- Where
- 17 sites in United States
- Volunteers
- 86 people
- Sponsor
- Remedy Pharmaceuticals, Inc.
Anthrax
Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
The purpose of this study is to: evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) as compared with either 90 mg/kg, 180 mg/kg or 360…
- Trial name
- NCT00845650
- Testing
- AIGIV 3.5 mg/kg, Gamunex 90 mg/kg, AIGIV 7.0 mg/kg
- Where
- United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Anthrax
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
The purpose of this Phase 3 clinical trial is to evaluate the immunogenicity and safety of BioThrax anthrax vaccine in healthy adults following 3 doses of BioThrax.
- Trial name
- NCT01491607
- Testing
- BioThrax
- Where
- 4 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Osmolality Disturbance, Lab Interference
Effect of Activated Charcoal on Serum Osmolality, Osmolal Gap, and Enzymatic Ethylene Glycol Assay
The goal of this observational study is to determine whether a clinically relevant dose of activated charcoal raises the serum osmolality and osmolal gap in a population of healthy volunteers.
- Trial name
- NCT07220031
- Testing
- Activated Charcoal
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University